The delisting is now final with no further appeal options. Expect continued low liquidity and potential further price erosion as remaining Nasdaq-market holders are forced to sell. Monitor for any reverse stock split or other compliance efforts, but near-term recovery appears unlikely.
Price Chart
Executive Summary
Nasdaq has filed a Form 25-NSE to remove Reviva Pharmaceuticals Holdings, Inc. from listing and registration, effective July 20, 2026, following the company's failure to maintain compliance with the minimum bid price rule (Listing Rule 5550(a)(2)). The delisting was finalized on June 26, 2026, after an unsuccessful appeal process. This confirms the loss of exchange listing, severely reducing liquidity and institutional access for RVPH shares.
Key Facts
- Delisting effective at the opening of trading on July 20, 2026.
- Company failed to meet Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
- Final delisting determination made on June 26, 2026.
- Stock has been suspended from Nasdaq since May 14, 2026, and now trades on OTC markets.
- Prior appeal and extension requests were denied; the company could not achieve compliance.
Financial Impact
Loss of Nasdaq listing eliminates exchange-traded liquidity and likely restricts institutional ownership, further pressuring the stock price on OTC markets.
Risk Factors
- Further price decline due to forced selling by institutional holders unable to hold OTC stocks.
- Potential loss of analyst coverage and reduced visibility for the company's pipeline.
- Risk of eventual deregistration if the company fails to meet OTC reporting requirements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (Primary) | 0001354457-26-000658 |
| Document: 0001354457-26-000658-index.html | 0001354457-26-000658 |
| Document: 0001354457-26-000658.txt | 0001354457-26-000658 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Press Release | $0.3521 $0.3521 | · 0.00% | ▲ +1.75% | $0.5000 (+42.01%) |
Jul 10, 2026 12w ago | 25-NSE | $0.6200 $0.4775 | ▲ +22.98% | ▲ +25.40% | $0.5000 (+19.35%) |
May 13, 2026 20w ago | Press Release | $0.3900 $0.6839 | ▼ −75.36% | ▼ −76.22% | $0.5000 (−28.21%) |
May 13, 2026 20w ago | 8-K | $0.3521 $0.7600 | ▼ −115.85% | ▼ −116.46% | $0.5000 (−42.01%) |
Apr 15, 2026 24w ago | 8-K | $0.8900 $0.8000 | ▼ −10.11% | ▼ −16.16% | $0.5000 (−43.82%) |
Mar 30, 2026 26w ago | Press Release | $0.6600 $0.8800 | ▲ +33.33% | ▲ +20.74% | $0.5000 (−24.24%) |
Mar 19, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▼ −2.41% | ▲ +5.21% | $0.5000 (+39.76%) |
Mar 18, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▲ +2.41% | ▼ −5.21% | $0.5000 (−39.76%) |
Mar 5, 2026 30w ago | 8-K | $4.20 $0.7200 | ▼ −82.86% | ▼ −79.07% | $0.5000 (−88.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access